Nanodropper and Lumata Health Launch Partnership Aimed at Improving Patient Care

Nanodropper recently announced a partnership with Lumata Health, which includes the launch of a pilot program bringing the Nanodropper Adaptor device to Lumata Health network patients across the United States. Lumata Health is a tech-enabled health care service company focused on preventing blindness from chronic eye conditions. It manages over 100,000 people at risk of vision loss and is backed by over $2 …

EyeD Pharma Raises $51 Million to Advance Intraocular Drug Implants

Belgium-based EyeD Pharma announced Dec. 22 that it had raised €45 million (US $51 million) in a funding round backed by a mix of private and public investors. The company said the funding would allow it to advance its lead candidate TimoD into human trials. TimoD is a non-biodegradable intraocular implant designed to deliver a controlled dose of the glaucoma drug …

Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastic

Santen unveiled plans to launch the first bio-based plastic eye drop bottle in the Europe, Middle East and Africa (EMEA) region. The plastic element of the bottles is made from a sugar cane-derived material called “I’m green Polyethylene.” This uses natural resources while maintaining the structural integrity of traditional plastic thus ensuring the medication is stable and reaches the patient in perfect condition, according to Santen. The bottles were introduced in Japan in June, 2021, followed by EMEA in early 2023. Santen’s efforts toward a …

Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDA

In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product. Eyenovia will provide additional information to the FDA, as requested in the CRL, as soon as possible, including information necessary to meet additional requirements under Genus Medical …